Results of the recent Merck Ad5 vaccine trial suggest that our current understanding of protective immunity in HIV infection is severely limited. As increasing evidence indicates that the early events in HIV infection determine the long-term outcome of this disease, integrated studies of acute HIV pathogenesis are warranted to identify the critical components of innate and adaptive immunity that ultimately impact viral control. While current HIV vaccine design strategies focus on inducing stronger and broader T cell responses, little consideration has been directed towards the selection of specific vaccine antigens and the quality of the antiviral immune response. We hypothesize that current vaccine approaches are not sufficiently focused with respect to antigen selection to induce the most protective and functional early T cell responses against the most critical regions of the virus, and that far more concerted efforts, both immunologically and virologically, is necessary to identify these critical regions. This Program Project Grant (PPG) represents an outgrowth of a long and productive effort to understand the immunologic and virologic events related to acute infection. During the previous period of support through the AIEDRP, we established an extensive cohort of persons with acute infection and identified key insights into the immunology and virology of acute infection. Here we propose to build upon this work to identify factors that we believe are fundamental to a protective antiviral immune response, including regions of HIV: (1) that are immunodominantly targeted by CD8+ T cell responses during acute HIV infection that exhibit strong antiviral activity. (2) that are rapidly processed into epitopes and presented by HLA alleles. (3) that are refractory to viral escape, or escape only at the cost to replicative fitness: and (4) that preferentially bind to stimulatory myelomonocytic receptors on myeloid dendritic cells. We believe that these vulnerable regions of HIV need to be identified to allow for the rational selection of specific antigenic regions for inclusion into a vaccine. In addition, it will be critical to determine how to best focus the vaccine-induced immune response against these regions, which will require an understanding of (5) what types of innate responses correlate with the induction of adaptive T cell responses with strong antiviral activity, and (6) what modifications to flanking regions of epitopes will enhance the antigen processing and presentation of the critical regions of HIV. This PPG application will provide highly relevant data for vaccine design regarding the earliest protective innate and adaptive immune responses, the parameters that define effective functional immune responses, and how these shape viral evolution and viral fitness.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
3P01AI074415-05S1
Application #
8721582
Study Section
Special Emphasis Panel (ZAI1-IPG-A (M2))
Program Officer
D'Souza, Patricia D
Project Start
2008-09-26
Project End
2014-08-31
Budget Start
2013-08-19
Budget End
2014-07-31
Support Year
5
Fiscal Year
2013
Total Cost
$1,715,563
Indirect Cost
$483,281
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Vaidya, Sagar A; Korner, Christian; Sirignano, Michael N et al. (2014) Tumor necrosis factor ? is associated with viral control and early disease progression in patients with HIV type 1 infection. J Infect Dis 210:1042-6
Schieffer, Miriam; Jessen, Heiko K; Oster, Alexander F et al. (2014) Induction of Gag-specific CD4 T cell responses during acute HIV infection is associated with improved viral control. J Virol 88:7357-66
Carlson, Jonathan M; Schaefer, Malinda; Monaco, Daniela C et al. (2014) HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science 345:1254031
Buzon, Maria J; Sun, Hong; Li, Chun et al. (2014) HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat Med 20:139-42
Palmer, Christine D; Tomassilli, Julia; Sirignano, Michael et al. (2014) Enhanced immune activation linked to endotoxemia in HIV-1 seronegative MSM. AIDS 28:2162-6
Buzon, Maria J; Martin-Gayo, Enrique; Pereyra, Florencia et al. (2014) Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol 88:10056-65
K├Ârner, Christian; Granoff, Mitchell E; Amero, Molly A et al. (2014) Increased frequency and function of KIR2DL1-3? NK cells in primary HIV-1 infection are determined by HLA-C group haplotypes. Eur J Immunol 44:2938-48
Foley, Maria Hottelet; Forcier, Talitha; McAndrew, Elizabeth et al. (2014) High avidity CD8+ T cells efficiently eliminate motile HIV-infected targets and execute a locally focused program of anti-viral function. PLoS One 9:e87873
Streeck, Hendrik; Lu, Richard; Beckwith, Noor et al. (2014) Emergence of individual HIV-specific CD8 T cell responses during primary HIV-1 infection can determine long-term disease outcome. J Virol 88:12793-801
Jost, Stephanie; Moreno-Nieves, Uriel Y; Garcia-Beltran, Wilfredo F et al. (2013) Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection. Retrovirology 10:74

Showing the most recent 10 out of 36 publications